Is It Possible To Reduce the Risk of Hepatocellular Carcinoma by TakingStatin in Diabeties Mellitus Patients with HBV or HCV

Objectives: To determine the relationship between the dose effect of Statin and the risk of HCC. Methods: This study was a case-control study. All participants were ≧ 50 years of age and were diagnosed with diabetes (ICD-9250.0x 0, 205.0 × 2) and were treated with an anti-diabetic agent for at least for 3 months according to the NHID, LHID2010 (longitudinal health insurance database 2010). We captured the use of a Statin before the index date in patients with type II diabetes. Patients diagnosed with a hepatoma (ICD-9:155) were defined as the case group. Results: The risk of hepatoma was reduced in patients with higher cumulative DDDs statin use compared to statin non-users. (HBV population: cumulative dose>298 DDDs: OR=0.41; 95% CI:0.24-0.72; HCV population: cumulative dose>205 DDDs: [OR=0.25; 95% CI: 0.13-0.48]). Conclusion: A dose-response relationship exists between lower risk of hepatoma and higher cumulative DDDs of statin use.